The ORR for the high-dose IL-2 group was 43%, while for the low-dose group was 35%.181In a phase 2 clinical trial, TIL treatment was effectively used to treat uveal melanoma; 35% (7/20) of patients showed an ORR, with 1 patient obtaining CR and 6 patients achieving PR.182 In a recent clinical trial, TIL in combination with high-dose IL-2 treatment for metastatic melanoma demonstrated an 80% disease control rate and a 36% ORR. The gene discussed is IL2; the disease is uveal melanoma.